

## RESEARCH ARTICLE

# Loss of *p15<sup>INK4b</sup>* Expression in Colorectal Cancer is Linked to Ethnic Origin

Wael Mohamed Abdel-Rahman<sup>1\*</sup>, Taina Tuulikki Nieminen<sup>2</sup>, Soheir Shoman<sup>3</sup>, Saad Eissa<sup>3</sup>, Paivi Peltomaki<sup>2</sup>

### Abstract

Colorectal cancers remain to be a common cause of cancer-related death. Early-onset cases as well as those of various ethnic origins have aggressive clinical features, the basis of which requires further exploration. The aim of this work was to examine the expression patterns of *p15<sup>INK4b</sup>* and SMAD4 in colorectal carcinoma of different ethnic origins. Fifty-five sporadic colorectal carcinoma of Egyptian origin, 25 of which were early onset, and 54 cancers of Finnish origin were immunohistochemically stained with antibodies against *p15<sup>INK4b</sup>* and SMAD4 proteins. Data were compared to the methylation status of the *p15<sup>INK4b</sup>* gene promoter. *p15<sup>INK4b</sup>* was totally lost or deficient (lost in  $\geq 50\%$  of tumor cell) in 47/55 (85%) tumors of Egyptian origin as compared to 6/50 (12%) tumors of Finnish origin ( $p=7e-15$ ). In the Egyptian cases with *p15<sup>INK4b</sup>* loss and available *p15<sup>INK4b</sup>* promoter methylation status, 89% of cases which lost *p15<sup>INK4b</sup>* expression were associated with *p15<sup>INK4b</sup>* gene promoter hypermethylation. SMAD4 was lost or deficient in 25/54 (46%) tumors of Egyptian origin and 28/48 (58%) tumors of Finnish origin. 22/54 (41%) Egyptian tumors showed combined loss/deficiency of both *p15<sup>INK4b</sup>* and SMAD4, while *p15<sup>INK4b</sup>* was selectively lost/deficient with positive SMAD4 expression in 24/54 (44%) tumors. Loss of *p15<sup>INK4b</sup>* was associated with older age at presentation ( $>50$  years) in the Egyptian tumors ( $p=0.04$ ). These data show for the first time that *p15<sup>INK4b</sup>* loss of expression marks a subset of colorectal cancers and ethnic origin may play a role in this selection. In a substantial number of cases, the loss was independent of SMAD4 but rather associated with *p15<sup>INK4b</sup>* gene promoter hypermethylation and old age which could be related to different environmental exposures.

**Keywords:** Colorectal cancer - immunohistochemistry - methylation - *p15<sup>INK4b</sup>* - SMAD4

*Asian Pac J Cancer Prev*, 15 (5), 2083-2087

### Introduction

*p15<sup>INK4b</sup>* (*CDKN2B*) is a tumor suppressor gene located, together with two other related genes *ARF* and *p16<sup>INK4a</sup>* (*CDKN2A*) within a 35 kb stretch on chromosome 9p21. The *INK4a/ARF/INK4b* locus is deleted in a variety of tumors including melanoma, pancreatic adenocarcinoma, glioblastoma, certain leukemias, non-small cell lung cancer, and bladder carcinoma (Kim Sharpless, 2006; Nakamura et al., 2011). The binding of the *INK4* proteins to the cyclin dependent kinases CDK4 and CDK6 abrogates the binding of these kinases to D-type cyclins, thus inhibiting CDK4/6-mediated phosphorylation of retinoblastoma (pRb) protein and its family members. Hypophosphorylated Rb-family proteins potently bind E2F transcription factors to exert a G1 cell-cycle arrest (Kim and Sharpless, 2006). Deregulation of pRb pathway is common in human cancers, but direct alterations of the pRb protein or its closely associated molecules are rarely observed in colorectal cancer apart from the infrequent

loss of *p16<sup>INK4a</sup>* expression associated with promoter methylation (Cheng et al., 2006; Joensuu et al., 2008). Colorectal cancers, however, undertake a more drastic upstream manoeuvre to deregulate the pRb-mediated cell cycle control through eliminating the growth inhibitory response to TGF- $\beta$  (Lu et al., 1995; Lampropoulos et al., 2012). In normal cells, binding of the TGF- $\beta$  to its receptor TGF- $\beta$ RII, causes phosphorylation of several SMAD proteins, such as SMAD3 and SMAD2 which form a heterodimeric complex with SMAD4. The SMAD3/SMAD4 (or SMAD2/SMAD4) dimer then migrates to the nucleus, where it teams up with MIZ-1 to induce expression of the *p15<sup>INK4b</sup>*. TGF- $\beta$  signalling also relieves *p15<sup>INK4b</sup>* from the *MYC*-induced repression by down regulating the *MYC* gene expression (Warner et al., 1999; Seoane et al., 2001). More recently, SMAD/STAT3 signaling pathway was shown to play a role in epithelial-to-mesenchymal transition during colorectal carcinogenesis (Zhu et al., 2013) and single nucleotide polymorphism (SNIP) variations within one of the

<sup>1</sup>College of Health Sciences, University of Sharjah, and Sharjah Institute for Medical Research, Sharjah, United Arab Emirates,

<sup>2</sup>Department of Medical Genetics, University of Helsinki, Helsinki, Finland, <sup>3</sup>Department of Pathology, National Cancer Institute, Cairo University, Cairo, Egypt \*For correspondence: whassan@sharjah.ac.ae

SMADs (*SMAD7*) have influenced the susceptibility to colorectal cancers (Nassiri et al., 2013).

We recently found remarkable frequent hypermethylation of the *p15<sup>INK4b</sup>* gene promoter in colorectal carcinoma of Egyptian origin (Nieminen et al., 2012). Conversely, hypermethylation of *p15<sup>INK4b</sup>* was reported mainly in glial tumors, leukemias, myelodysplasia (Esteller et al., 2001), hepatocellular carcinoma (Zekri Ael et al., 2013) and, more recently, in peripheral blood of leukemia patients (Bodoor et al., 2014), but was not a common finding in colorectal carcinoma of Western origin (Cheng et al., 2006; Nieminen et al., 2012). Interestingly, *p15<sup>INK4b</sup>* methylation was detected in 68% of colorectal cancer specimens of Chinese origin (Xu et al., 2004) and in 26% colorectal cancers from Japan (Ishiguro et al., 2006). Egyptian colorectal carcinoma is surprisingly young age disease with high proportion of rectal and advanced stage cancers. The *p15<sup>INK4b</sup>* methylation data could explain these clinical differences and link them to exposure to environmental toxins, since gene methylation may be related to different environmental exposures.

Here, we characterized sporadic colorectal cancers of Egyptian and Finnish origins for expression of *p15<sup>INK4b</sup>* and its closely related upstream protein SMAD4 by immunohistochemistry staining and correlated the results with the clinico-pathological and gene methylation data available on this series.

## Materials and Methods

### Patients and samples

This study was performed on a consecutive series of 55 Egyptian carcinoma and 54 cancers of Finnish origin (Table 1). These cases were selected from a bigger series (Nieminen et al., 2012) according to the availability of immunohistochemistry tissue sections. Samples were collected, from formalin fixed paraffin embedded tissue blocks of surgical resection specimens as explained previously (Nieminen et al., 2012). DNA was extracted from paraffin-embedded specimens by standard techniques. Mutation screening, microsatellite instability (MSI), methylation analyses and p53 immunohistochemistry were performed in previous studies (Joensuu et al., 2008; Nieminen et al., 2012). The work was conducted at Helsinki under the approval of

**Table 1. Pathological and Molecular Characteristics of the Egyptian vs Western tumors**

	Egypt	Finn sporadic
No. of tumors in the original series	69	61
No. included in the current study	55	50
No. included in methylation analysis	43	34
Age range (average)	18-78 (54.8)	52-95 (73.6)
Gender (M:F)	1.23:1	0.5:1
Tumor site (Rt : Lt : Rectal)	15:21:33	35:17:4*
MSI frequency	19/61a (31%)	16/61 (26%)
p53 stabilization	43/68 (63%)	29/57 (51%)
Nuclear $\beta$ -catenin	28/68 (41%)	45/58 (78%)
TSGMP phenotype ( $\geq 5$ genes methylated)	22/43 (51%)	14/51 (27%)

\*Variation in the numbers or denominator used for calculating percentages resulted from missing data. Molecular data were generated in previous study (Nieminen et al., 2012). MSI, microsatellite instability; TSGMP, tumor suppressor gene methylator phenotype

the institutional review boards of the Helsinki University Central Hospital.

### Immunohistochemistry

Four-micrometer sections from formalin-fixed paraffin-embedded tissues were de-waxed and re-hydrated to distilled water then sections were subject to heat-induced target retrieval in 1 mM ethylenediaminetetraacetic acid (EDTA) buffer pH 8.0 for 5 minutes at 750 W followed by 5 minutes at 450 W in a microwave oven. After cooling, the slides were washed in Tris-buffered saline/Tween 20 pH 7.2 and subsequent staining steps were performed manually with the Dako EnVision+ System, Peroxidase (DAB), according to manufacturer's instructions (Dako, Glostrup, Denmark). Additionally, after blocking endogenous peroxidase activity, and prior to incubation with the primary antibody, the sections were incubated with 10% normal (non-immune) goat serum (Dako, Glostrup, Denmark) for 30 minutes. The primary antibodies were: anti *p15<sup>INK4b</sup>* mouse monoclonal antibody clone 15P06 used at dilution 1:25 and anti SMAD4 rabbit monoclonal antibody clone EP618Y at dilution 1:200. Both antibodies were purchased from Abcam (Cambridge, UK). Primary antibody incubation was for 2 hours at room temperature. Paired tumor and normal mucosa were in the same section and the normal tissues were used as internal reference for evaluation of staining results.

### Interpretation of staining results

Interpretation of staining results was performed by experienced histopathologist (WMA-R) SMAD4 staining was cytoplasmic in normal mucosa and neoplastic cells. Tumors showing positive staining in more than 50% of neoplastic cells were considered positive, tumors showing staining in less than 50% of neoplastic cells were considered 'deficient' while tumors showing staining of less than 2% of neoplastic were considered negative. The cut-off level of 50% was according to Sakellariou et al (Sakellariou et al., 2008). *p15<sup>INK4b</sup>* expression was nuclear and a scoring scale similar to the one described above with a 50% cut-off level was employed according to the published literature (Oda et al., 2005; Endo et al., 2011).


### Statistical analysis

Fisher's exact probability test was used to evaluate differences between groups. Analyses were performed using MS Excel and/or VassarStats Web-based statistical program <http://faculty.vassar.edu/lowry/VassarStats.html>. All reported p values were two-tailed and p values < 0.05 were considered significant.


## Results

### Immunohistochemistry *p15<sup>INK4b</sup>* and SMAD4

The analyses showed that *p15<sup>INK4b</sup>* was totally lost or deficient (lost in  $\geq 50\%$  of tumor cell) in 47/55 (85%) tumors of Egyptian origin as compared to 6/50 (12%) tumors of Finnish origin ( $p=7e-15$ ). SMAD4 was lost or deficient in 25/54 (46%) tumors of Egyptian origin and 28/48 (58%) tumors of Finnish origin. 22/54 (41%) Egyptian tumors showed combined loss/deficiency of both



**Figure 1. Diagrammatic Comparison between the SMAD4 and *p15<sup>INK4b</sup>* Results from the Egyptian Tumors (top) and Finnish Tumors (bottom).** Black boxes under the immunohistochemistry heading indicate deficient/lost expression, while the black boxes under methylation indicate methylated *p15<sup>INK4b</sup>* promotor. The hatched/grey boxes indicate that data were not available for these cases. The number of cases in each category is indicated on the top



**Figure 2. *p15<sup>INK4b</sup>* and SMAD4 Immunohistochemistry.** A, positive nuclear staining of *p15<sup>INK4b</sup>* in carcinoma; B, loss of *p15<sup>INK4b</sup>* staining in carcinoma; C, positive cytoplasmic staining of SMAD4 in carcinoma; D, loss of SMAD4 expression in carcinoma compared to normal mucosa (upper right corner). Original magnification  $\times 100$

**Table 2. Expression *p15<sup>INK4b</sup>* in Relation to Clinicopathological and Molecular Features of Egyptian Colorectal Cancer**

		<i>p15<sup>INK4b</sup></i> positive n/(%)	<i>p15<sup>INK4b</sup></i> reduced or negative n/(%)	p value
Gender	Male	4 (13%)	27 (87%)	0.7
	Female	4 (17%)	20 (83%)	
Age	$\leq 50$	8 (23%)	27 (77%)	0.04
	$> 50$	0 (0%)	20 (100%)	
Differentiation	Good/moderate	4 (12%)	28 (88%)	1
	Poor	3 (13%)	20 (87%)	
Stage	Early (I&II)	3	14	1
	Late (III& IV)	5	30	
Location	Right	3	9	0.7
	Left/rectal	7	36	
MSI status	MSI	3	12	0.7
	MSS	5	33	
p53	Negative	2	22	0.3
	Stabilized	6	24	
$\beta$ -catenin	Membranous	7	22	0.1
	Nuclear	2	24	

*p15<sup>INK4b</sup>* and SMAD4, while *p15<sup>INK4b</sup>* was selectively lost/deficient with positive SMAD4 expression in 24/54 (44%) (Figure 1, 2).

#### Correlation of *p15<sup>INK4b</sup>* expression and methylation status

The available *p15<sup>INK4b</sup>* promotor methylation data showed more frequent methylation in the Egyptian series

(28/42; 67%) compared to the Finnish series (1/33; 3%;  $p=7e-9$ ). In the Egyptian cases with *p15<sup>INK4b</sup>* loss and available *p15<sup>INK4b</sup>* promotor methylation status, 89% of cases which lost *p15<sup>INK4b</sup>* expression were associated with *p15<sup>INK4b</sup>* gene promotor hypermethylation (Figure 1).

#### Relationship between *p15<sup>INK4b</sup>* expression and pathological and molecular features

Table 2 shows *p15<sup>INK4b</sup>* expression in relation to the clinico-pathological and molecular features of the Egyptian tumors. Significant correlation was found between older age at presentation ( $>50$  years) and the loss of *p15<sup>INK4b</sup>* ( $p=0.04$ ). No significant relation was found between *p15<sup>INK4b</sup>* expression and microsatellite instability status, p53 expression, or  $\beta$ -catenin localization.

## Discussion

Prompted by our finding of remarkable *p15<sup>INK4b</sup>* promotor methylation in colorectal cancers of Egyptian origin (Nieminen et al., 2012), we have analysed the immunohistochemical expression of *p15<sup>INK4b</sup>* and SMAD4 in colorectal cancers of Egyptian and Western origins with the purpose to exploit these markers in diagnosis and personalized medicine. The results of the present study lead us to speculate that the loss of *p15<sup>INK4b</sup>* protein expression marks the development of subsets of colorectal cancers of Eastern origins. This is supported by the methylation data on colorectal cancers of Chinese (Xu et al., 2004) and Japanese origin (Ishiguro et al., 2006). SMAD4 expression was lost or deficient in around half of the tumors examined of both Egyptian and Finnish origin consistent with the published literature (Royce et al., 2010; Ahn et al., 2011). SMAD4 is a potential upstream inducer of *p15<sup>INK4b</sup>* (see introduction). Hence, some cases of *p15<sup>INK4b</sup>* loss could be attributed to SMAD4 deficiency, but, SMAD4 deficiency cannot be considered sufficient to explain the remarkable loss of *p15<sup>INK4b</sup>* in the Egyptian tumors since it was not associated with similar *p15<sup>INK4b</sup>* loss in the Finn cancers.

The loss of *p15<sup>INK4b</sup>* expression was reported in non-epithelial malignancies including leukemias, malignant peripheral nerve sheath tumors, meningioma, and melanoma (Herman et al., 1997; Teofili et al., 2000; Simon et al., 2001; Endo et al., 2011). Furthermore, in support of our present findings, immunohistochemical expression studies of *p15<sup>INK4b</sup>* in epithelial cancers showed substantial loss in a lineage specific fashion. Sakellariou and co-workers reported *p15<sup>INK4b</sup>* loss in more than 70% of advanced gastric cancers, especially the intestinal subtype (Sakellariou et al., 2008). Consistent with our data, no correlation was observed between *p15<sup>INK4b</sup>* and pathological or survival data apart from tendency to affect male gender and distal location within the stomach (Sakellariou et al., 2008). In cutaneous squamous cell carcinoma, *p15<sup>INK4b</sup>* protein expression was absent in the majority of cases (69%) but, there was no significant relationship between clinicopathologic variables of the patients (age, sex and tumor grade) and *p15<sup>INK4b</sup>* protein expression (Moad et al., 2009). More recently, Holm et al reported loss of *p15<sup>INK4b</sup>* in 82% of vulvar squamous cell

carcinomas which correlated significantly with increased invasiveness. However, they could not establish p15<sup>INK4b</sup> as independent prognostic markers (Holm et al., 2013).

Interestingly, the loss p15<sup>INK4b</sup> in the Egyptian series was associated with its gene promoter methylation and with old age at onset suggesting a potential causal relationship. While tumor suppressor promoter methylation is known to increase with age (Fraga et al., 2007), aging alone seems insufficient to explain our data given the higher average age at onset of colorectal cancer (Table 1) but significantly less frequent methylation in the Finnish series (Figure 1). Paun et al 2010 demonstrated that environmental toxins such as smoking were associated with gene methylation in the normal rectal mucosa and with the presence of colorectal adenomas. These methylated genes were potentially involved in early stages of adenoma formation and the authors speculated that the observed epigenetic alterations in these markers may be caused in part by the effects of smoking and/or age (Paun et al., 2010). Exposures to environmental toxicants and toxins might cause epigenetic changes (O'Hagan, 2013; Coppede et al., 2014; Senut et al., 2014) and it is clear that many different adverse environmental factors are likely to exist in the East compared to the West as discussed previously (Nieminen et al., 2012). Our data, together with the available literature (Belinsky et al., 2004; Marsit et al., 2006) suggest a link between environmental exposures, epigenetic changes and cancers development, which remains to be confirmed in experimental models and large series of clinical samples.

## Acknowledgements

This work was supported by the Terry Fox Foundation (W.M.A.-R.) and Sigrid Juselius Foundation (W.M.A.-R. & P.P.), the Finnish Cancer Organizations (P.P.), Academy of Finland grant no. 257795 (P. P.), Biocentrum Helsinki (P. P.), and European Research Council grant no. FP7-ERC-232635 (P. P.). The authors thank Saila Saarinen for expert technical assistance.

## References

Ahn BK, Jang SH, Paik SS, et al (2011). Smad4 may help to identify a subset of colorectal cancer patients with early recurrence after curative therapy. *Hepatology*, **58**, 1933-6.

Belinsky SA, Klinge DM, Liechty KC, et al (2004). Plutonium targets the p16 gene for inactivation by promoter hypermethylation in human lung adenocarcinoma. *Carcinogenesis*, **25**, 1063-7.

Bodoor K, Haddad Y, Alkhateeb A, et al (2014). DNA Hypermethylation of Cell Cycle (p15 and p16) and Apoptotic (p14, p53, DAPK and TMS1) Genes in Peripheral Blood of Leukemia Patients. *Asian Pac J Cancer Prev*, **15**, 75-84.

Cheng YW, Shawber C, Notterman D, et al (2006). Multiplexed profiling of candidate genes for CpG island methylation status using a flexible PCR/LDR/Universal Array assay. *Genome Res*, **16**, 282-9.

Coppede F, Migheli F, Lopomo A, et al (2014). Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens: Correlation with physiological and pathological characteristics, and with biomarkers of one-carbon metabolism. *Epigenetics*, 9 [Epub ahead of print].

Endo M, Kobayashi C, Setsu N, et al (2011). Prognostic significance of p14ARF, p15<sup>INK4b</sup>, and p16<sup>INK4a</sup> inactivation in malignant peripheral nerve sheath tumors. *Clin Cancer Res*, **17**, 3771-82.

Esteller M, Corn PG, Baylin SB, et al (2001). A gene hypermethylation profile of human cancer. *Cancer Res*, **61**, 3225-9.

Fraga MF, Agrelo R and Esteller M (2007). Cross-talk between aging and cancer: the epigenetic language. *Ann N Y Acad Sci*, **1100**, 60-74.

Herman JG, Civin CI, Issa JPJ, et al (1997). Distinct patterns of inactivation of p15<sup>INK4B</sup> and p16<sup>INK4A</sup> characterize the major types of hematological malignancies. *Cancer Research*, **57**, 837-41.

Holm R, Forsund M, Nguyen MT, et al (2013). Expression of p15INK(4)b and p57KIP(2) and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma. *PLoS One*, **8**, 61273.

Ishiguro A, Takahata T, Saito M, et al (2006). Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer. *J Gastroenterol Hepatol*, **21**, 1334-9.

Joensuu EI, Abdel-Rahman WM, Ollikainen M, et al (2008). Epigenetic signatures of familial cancer are characteristic of tumor type and family category. *Cancer Res*, **68**, 4597-605.

Kim WY and Sharpless NE (2006). The regulation of INK4/ARF in cancer and aging. *Cell*, **127**, 265-75.

Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, et al (2012). TGF-beta signalling in colon carcinogenesis. *Cancer Lett*, **314**, 1-7.

Lu SL, Akiyama Y, Nagasaki H, et al (1995). Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. *Biochem Biophys Res Commun*, **216**, 452-7.

Marsit CJ, Karagas MR, Danaee H, et al (2006). Carcinogen exposure and gene promoter hypermethylation in bladder cancer. *Carcinogenesis*, **27**, 112-6.

Moad AI, Lan TM, Kaur G, et al (2009). Immunohistochemical determination of the P15 protein expression in cutaneous squamous cell carcinoma. *J Cutan Pathol*, **36**, 183-9.

Nakamura H, Makino K, Kuratsu J (2011). Molecular and clinical analysis of glioblastoma with an oligodendroglial component (GBMO). *Brain Tumor Pathol*, **28**, 185-90.

Nassiri M, Kooshyar MM, Roudbar Z, et al (2013). Genes and SNPs associated with non-hereditary and hereditary colorectal cancer. *Asian Pac J Cancer Prev*, **14**, 5609-14.

Nieminen TT, Shoman S, Eissa S, et al (2012). Distinct genetic and epigenetic signatures of colorectal cancers according to ethnic origin. *Cancer Epidemiol Biomarkers Prev*, **21**, 202-11.

O'Hagan HM (2013). Chromatin modifications during repair of environmental exposure-induced DNA damage: A potential mechanism for stable epigenetic alterations. *Environ Mol Mutagen*. **55**, 278-91

Oda Y, Yamamoto H, Takahira T, et al (2005). Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. *J Pathol*, **207**, 410-21.

Paun BC, Kukuruga D, Jin Z, et al (2010). Relation between normal rectal methylation, smoking status, and the presence or absence of colorectal adenomas. *Cancer*, **116**, 4495-501.

Royce SG, Alsop K, Haydon A, et al (2010). The role of SMAD4 in early-onset colorectal cancer. *Colorectal Dis*, **12**, 213-9.

Sakellariou S, Liakakos T, Ghiconti I, et al (2008). Immunohistochemical expression of P15 (INK4B) and SMAD4 in advanced gastric cancer. *Anticancer Res*, **28**,

1079-83.

- Senut MC, Sen A, Cingolani P, et al (2014). Lead exposure disrupts global dna methylation in human embryonic stem cells and alters their neuronal differentiation. *Toxicol Sci*, [Epub ahead of print].
- Seoane J, Pouponnot C, Staller P, et al (2001). TGFbeta influences MYC, Miz-1 and Smad to control the CDK inhibitor p15<sup>INK4b</sup>. *Nat Cell Biol*, **3**, 400-8.
- Simon M, Park TW, Koster G, et al (2001). Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression. *J Neurooncol*, **55**, 149-58.
- Teofili L, Morosetti R, Martini M, et al (2000). Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation. *Exp Hematol*, **28**, 519-26.
- Warner BJ, Blain SW, Seoane J, et al (1999). MYC downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway. *Mol Cell Biol*, **19**, 5913-22.
- Xu XL, Yu J, Zhang HY, et al (2004). Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. *World J Gastroenterol*, **10**, 3441-54.
- Zekri Ael R, Nassar AA, El-Din El-Rouby MN, et al (2013). Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. *Asian Pac J Cancer Prev*, **14**, 6721-6.
- Zhu QC, Gao RY, Wu W, et al (2013). Epithelial-mesenchymal transition and its role in the pathogenesis of colorectal cancer. *Asian Pac J Cancer Prev*, **14**, 2689-98.